Gossamer Bio to Present at Upcoming Investor Conferences

Gossamer Bio to Present at Upcoming Investor Conferences

August 29, 2025 | Last Trade: US$3.14 0.20 -5.99

SAN DIEGO / Aug 29, 2025 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present at the following investor conferences in September.

Cantor Global Healthcare Conference

Date / Time:	September 3rd, at 9:10 AM ET
Format:	Fireside Chat & 1x1’s
Location:	New York, NY
Webcast Link:	https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=93028624&checkCompany=1&checkEmail=1&checkName=1

Wells Fargo Healthcare Conference

Date / Time:	September 4th
Format:	1x1’s
Location:	Boston, MA

H.C. Wainwright 27th Annual Global Healthcare

Date / Time:	September 9th, at 8:00 AM ET
Format:	Fireside Chat & 1x1’s
Location:	New York, NY

About Gossamer Bio

Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.

Stock Quote

Last Trade:	US$3.14
Daily Change:	-0.20 -5.99
Daily Volume:	5,139,100
Market Cap:	US$726.780M

November 05, 2025 Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update September 25, 2025 Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension September 22, 2025 Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025 August 05, 2025 Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update June 16, 2025 Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH LOAD MORE NEWS

Featured Stock

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE